Related Experiment Videos
[Use of platelet antiaggregating agents in acute coronary syndromes]
María de Lourdes Torres Peláez1, Catalina Santiago Arana
1Unidad Coronaria, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D. F.
Insights
Platelet IIb/IIIa receptor blockers improve outcomes in acute coronary syndromes but carry bleeding risks and high costs. Further research is needed to optimize their use and identify suitable patient populations.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Context:
- Platelets are key in acute coronary syndromes (ACS) pathogenesis.
- Aspirin's limited efficacy drives research into novel antiplatelet agents.
- Platelet IIb/IIIa receptor blockers are investigated for ACS management.
Purpose:
- To review the efficacy and limitations of platelet IIb/IIIa receptor blockers in ACS.
- To highlight unresolved issues regarding their clinical application.
- To emphasize the need for targeted patient selection and nursing knowledge.
Summary:
- Platelet IIb/IIIa blockers show promise in ACS, particularly with percutaneous coronary revascularization.
- High cost and bleeding risks limit their widespread use.
- Oral IIb/IIIa antagonists have not surpassed aspirin's efficacy.
- Optimal dosage, treatment duration, and comparative efficacy require further study.
Impact:
- Improved patient outcomes in specific ACS settings.
- Need for careful patient selection to balance benefits against risks and costs.
- Importance of healthcare professionals, especially nurses, understanding these agents for safe and effective patient care.
Abstract:
Nowadays, it is known that platelets are the main agents involved in the pathogenesis of acute coronary syndromes, and the fact that aspirin is a weak antiplatelet agent has led to an intensive research in antiplatelet drugs in the last years. The medical literature from the last decade contains many studies on the use of platelet IIb/IIIa receptor blockers in different clinical settings. Agents that block the IIb/IIIa platelet receptor have shown to be useful in improving prognosis of patients with acute coronary syndromes (ACS), especially in those studies of percutaneous coronary revascularization procedures. However, their potential risk of causing bleeding and high cost have prevented applied universal and routine application. There are some aspects, such as correct dosage, optimal duration of treatment, and direct comparison of the efficacy of different types of IIb/IIIa blockers, that not have not been resolved yet. On the other hand, oral IIb/IIIa antagonists have not exceeded the efficacy of aspirin. Finally, it is necessary to identify those patients that will obtain the most benefit from this treatment to avoid unnecessary risks and costs. Therefore, it is very important, for the nurse to have the necessary knowledge on the therapeutic effect and use of this antiplatelets therapy, to be able to identify in time any complication that night increase the risk and in danger the patient's life.